Mitchell Clark, MD, MPH
Assistant Professor of Obstetrics, Gynecology & Reproductive SciencesCards
About
Research
Publications
2024
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.Peer-Reviewed Original ResearchDiagnostic experiences of Black and White patients with uterine cancer: A qualitative study
Britton M, Izampuye E, Clark M, Ornstein R, Nunez-Smith M, Wright J, Xu X. Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study. Gynecologic Oncology 2024, 191: 67-73. PMID: 39362045, DOI: 10.1016/j.ygyno.2024.09.010.Peer-Reviewed Original ResearchDiagnosis of uterine cancerUterine cancerRacial disparitiesHealthcare systemSocial determinants of healthNon-Hispanic White (WhiteGynecologic careDeterminants of healthDiscriminatory experiencesSemi-structured interviewsPatient engagementSocial determinantsAcceptance of discomfortHealthcare accessPerceived barriersPatient experienceThematic analysisDiagnostic journeyQualitative studyAudio-recordedBlack respondentsWhite patientsNegative experiencesHealthcareStage II-IV diseaseTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.Peer-Reviewed Original ResearchHigh-grade serous ovarian cancerClear cell carcinomaHER2-targeting antibody-drug conjugateAntibody-drug conjugatesT-DXdReceptor over-expressionTrastuzumab deruxtecanXenograft modelCell linesOvarian clear cell carcinomaOvarian cancer cell linesTumors overexpressing HER2Biologically aggressive tumorsFluorescence in situ hybridization assaySerous ovarian cancerEffective antibody-drug conjugatesIn vivo antitumor activityMouse xenograft modelMetastatic cell linesDS-8201aCancer cell linesAggressive tumorsHER2 expressionCell carcinomaOvarian cancerRandomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-freePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatientsRandomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimodCorrection: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.Peer-Reviewed Original Research
2023
Black-White differences in uterine cancer symptomatology and stage at diagnosis
Xu X, Chen L, Nunez-Smith M, Clark M, Ferris J, Hershman D, Wright J. Black-White differences in uterine cancer symptomatology and stage at diagnosis. Gynecologic Oncology 2023, 180: 118-125. PMID: 38091770, PMCID: PMC10922746, DOI: 10.1016/j.ygyno.2023.11.029.Peer-Reviewed Original ResearchAdvanced stage diagnosisWhite patientsPostmenopausal bleedingPatient characteristicsEnd Results-Medicare databaseBlack-white differencesBlack-White disparitiesBlack patientsUterine cancerCancer symptomsHigh riskPatientsAdvanced stageSymptomsDiagnosisCancer symptomatologyRegression modelsRiskLarge proportionBleedingHistologyCancerEpidemiologySymptomatologyMonthsICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging
AlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.Peer-Reviewed Original ResearchEndometrial cancer stagingSentinel lymph nodesLymph nodesCancer stagingSentinel lymph node identificationICG fluorescence techniqueTertiary care hospitalLymph node identificationICG techniqueSentinel lymphCare hospitalIntervention useStagingDye techniqueNode identificationLymphPatientsMalignancyHospitalTimeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims data
Xu X, Chen L, Nunez-Smith M, Clark M, Wright J. Timeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims data. PLOS ONE 2023, 18: e0289692. PMID: 37682914, PMCID: PMC10490884, DOI: 10.1371/journal.pone.0289692.Peer-Reviewed Original ResearchConceptsPostmenopausal bleedingFirst diagnostic procedureDiagnostic evaluationDiagnostic proceduresGynecologic conditionsMedicaid patientsCox proportional hazards modelPrompt diagnostic evaluationRetrospective cohort studyMarketScan Research DatabasesAdditional risk factorsNon-clinical factorsCommon gynecologic conditionProportional hazards modelLower ratesCohort studyMost patientsPatient characteristicsBenign etiologyGynecologic cancerCancer patientsPreventive careUterine cancerInsurance typeRisk factorsIn Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaAntibody-dependent cellular cytotoxicityT-DXdUSC patientsUSC cell linesTrastuzumab deruxtecanSerous carcinomaHER2 expressionClinical trialsRecurrent uterine serous carcinomaTopoisomerase I inhibitor payloadSignificant antibody-dependent cellular cytotoxicityCell linesMultiple tumor indicationsPrimary USC cell linesLow HER2 expressionFuture clinical trialsHigh recurrence ratePeripheral blood lymphocytesERBB2 gene amplificationGrowth suppressionHER2-overexpressing cell linesTumor growth suppressionOverall survivalStandard chemotherapy
Academic Achievements & Community Involvement
Clinical Care
Overview
Mitchell Clark, MD, is a gynecologic oncologist with training in both surgical and medical oncology. He has expertise in chemotherapy, targeted therapies, and minimally invasive surgeries. He sees women with gynecologic malignancies and complex surgical problems, as well as genetic conditions that put them at risk for developing a gynecologic cancer.
Dr. Clark grew up in a small, rural community, where he began thinking about becoming a doctor after a close family member died from ovarian cancer. “I saw the lack of resources and advanced treatment options, and limitations in the system,” he says. “I was inspired to pursue a specialty where I could advocate for women to receive the highest quality of care close to home.”
Since then he’s seen improvements in both treatments and survival rates for women with gynecologic cancers. Surgery has evolved to the point where he can usually offer a minimally invasive approach that not only treats cancer, but also allows patients to return to their normal routines “faster than ever,” he says. “Being at Yale allows me to offer comprehensive cancer care that encompasses a multidisciplinary approach spanning from early detection to survivorship.”
In addition to caring for patients, Dr. Clark is interested in improving care for his patients through research. “I am passionate about leveraging the power of large health care administrative databases that include thousands of women to try and answer the important questions facing our specialty,” he says. Another interest is early detection and prevention of cervical cancer. “We know that most cervical cancers are due to human papillomavirus [HPV] infections, which can be prevented through vaccination,” Dr. Clark says.
Clinical Specialties
Fact Sheets
Peritoneal Cancer
Learn More on Yale MedicineVaginal Cancer
Learn More on Yale MedicineGynecologic Cancers
Learn More on Yale MedicineGestational Trophoblastic Tumors
Learn More on Yale Medicine
Board Certifications
Gynecologic Oncology
- Certification Organization
- Royal College of Physicians & Surgeons of CANADA
- Original Certification Date
- 2020
Obstetrics & Gynecology
- Certification Organization
- Royal College of Physicians & Surgeons of CANADA
- Original Certification Date
- 2018
Yale Medicine News
News & Links
News
- November 07, 2024
Yale Ob/Gyn Faculty Present the Latest in Gynecologic Oncology at Memorial Conference
- October 24, 2024
Benefits Go Beyond Summer for YSM Research Program
- July 16, 2024
Smilow Cancer Hospital at Waterford earns accreditation with commendation from Commission on Cancer, American College of Surgeons
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments